1
In the multivariate Cox analysis, RBV ranges remained independent and significant outcome predictors.
2
No additional benefits of RBV use were observed for both regimens.
3
Selection towards a dominant IFN-resistant strain did not occur under standard or PEG-IFN plus RBV.
4
Conclusion: Quantitative whole-animal absorption reconstruction is possible and can be validated in vivo using the rBV.
5
Only individuals who had completed a course of pegIFN-RBV therapy and had validated outcomes were considered.
6
The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV containing regimens.
7
The absorption values correlated strongly with the rBV-based absorption values, confirming the accuracy of the absorption reconstruction.
8
Consequently, we found that RBV-resistant phenotype was conferred mainly by host factor and partially by viral factor.
9
In about one-third of patients the RBV was within these ranges and in two-thirds it was above.
10
Objectives: To evaluate safety and efficacy of RBV in the era of DAAs in chronic HCV Egyptian patients.
11
In conclusion, occurrence of HCC is not a rare event during and immediately after peginterferon-alfa-2a plus RBV treatment.
12
For muscle and subcutaneous tumors, which have a much lower rBV and absorption, absorption reconstruction was less important.
13
Patients on ADJ higher doses of RBV experienced higher rates of anemia and require more erythropoietin without increasing SVR.
14
These colonies were mixed together and further treated with high doses of RBV (up to 200 μM).
15
Only 41 received RBV.
16
Conclusions: Particular amino acid changes in the NS5B region of HCV may correlate with outcomes of IFN plus RBV combination therapy.